Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Rx Card Sponsors Are Passing On 80%-90% of Discounts, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS is collecting some aggregate data to monitor rebate pass-through, Administrator McClellan notes. Enforcement actions – and the price transparency of public retail prices – incentivize sponsors to pass discounts to beneficiaries, CMS says.

You may also be interested in...

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

Pfizer In Talks With FDA Over Viagra Label Update To Reflect Vision Loss

Discussions follow an FDA investigation prompted by journal article reporting 15 cases of non-arteritic anterior ischemic optic neuropathy in sildenafil patients. Pfizer said a review of 103 clinical trials found no reports of the NAION; the company has submitted 23 cases to FDA since Viagra entered the market in 1998.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts